60P attends the 10th Annual European Life Sciences CEO Forum (ELSCEO) as a presenter and a partnering company.
60P attends AusBiotech Series.
60P attends International Bio as a presenting and partnering company.
Priority Review Designation Received for Tafenoquine
READ MORE
60P received Priority Review Designation from the USFDA for Tafenoquine (TQ) for prevention of malaria in adults
READ MORE
US Army Medical Research Lab Gets Fast Track Approval from USFDA for Malaria Drug
60 Degrees Pharmaceuticals Fast Tracked For Malaria Drug
READ MORE
60P Submits New Drug Application to USFDA for Antimalarial Drug Tafenoquine
READ MORE
60P’s investigational antimalarial agent tafenoquine is shown to be free of neurologic toxicity in adult rats according to recent study findings.
READ MORE
60P has received the first tranche of $4 million in a debt financing deal with Knight Therapeutics Inc. in support of our drug development program for tropical diseases.
READ MORE
60P has received approval to conduct a clinical study with celgosivir and modipafant in dengue patients in collaboration with Singapore General Hospital.
READ MORE
60P recently entered into a cooperative research and development agreement with the US Army to commercialize 60P003 (Tafenoquine) for malaria prophylaxis.
READ MORE
60P recently entered into an exclusive licensing deal with SingHealth and Duke-National University of Singapore Graduate Medical School to further develop celgosivir (60P001) for dengue fever.
One of 60P’s partners, Duke-NUS Medical School and its collaborators, completed a Phase I clinical study that demonstrated the safety of celgosivir in dengue patients and a trend toward faster NS1 clearance, suggesting the possibility of mitigating vascular permeability syndrome using glucosidase inhibitors.
READ MORE
60P has entered into a research collaboration agreement with the Duke-NUS Medical School to investigate the utility of different combinations of dengue drugs. Dengue, like other viral diseases, will likely require a combination of different host and virus-targeted molecules to achieve useful clinical benefit. Studies performed by Dr. Subhash Vasudevan.
60P established a subsidiary, 60P Australia, Pty. Ltd. 60P Australia will take the lead in continuing the company’s development of dengue therapeutics.
Report suggests that the incidence of dengue may have been underestimated by a factor of three. Therefore, prior estimates, including our own, of economic burden and the potential market for dengue drugs, will need to be revised upward.
READ MORE
60P estimates the potential market for dengue drugs to be $338 million annually. Published in Antiviral Research, the study was based on publicly available information regarding medical costs and lost productivity associated with clinical cases of dengue that result in an estimated economic burden of at least $1.7 billion a year.
READ MORE
Cases and 1 Million+ deaths in the U.S. from COVID-19 infections
Annual deaths from malaria globally
Travelers to malaria endemic regions per annum
Annual dengue infections globally
1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036